# Skeptic's Evaluation of EV-Derived Biomarker Hypotheses for Early AD
---
## Hypothesis 1: NDEV p-tau231 as Ultra-Early Diagnostic Marker
### Strongest Specific Weakness: Citation Misattribution and Mechanistic Imprecision
The hypothesis claims "Winston et al. (2019) demonstrated that NDEV p-tau181 discriminates AD from controls with AUC > 0.90" as key supporting evidence for p-tau231. This is a conflation of distinct phospho-epitopes. Winston et al. (2019, PMID: 31278165) specifically validated **NDEV p-tau181**, not p-tau231. The evidentiary foundation for p-tau231 is considerably weaker than presented—you've borrowed the credibility of one epitope to support another without establishing equivalent evidence.
The mechanistic claim that p-tau231 "occurs upstream" in the tau seeding cascade is also imprecise. Phosphorylation at multiple sites (T181, T217, T231, S396) reflects the activity of overlapping kinase families (GSK-3β, CDK5, DYRK1A) acting in parallel on soluble tau, not a strictly sequential cascade. Regional and cellular context matters enormously.
### Counter-Evidence and Known Complications
1. **Ultrasensitive plasma p-tau assays now perform exceptionally well in preclinical populations.** Janelidze et al. (2020, PMID: 32053791) and Palmqvist et al. (2025) demonstrated plasma p-tau217 AUC > 0.90 for detecting amyloid positivity in cognitively unimpaired individuals. The assumption that plasma assays lack sensitivity in preclinical stages is increasingly obsolete.
2. **L1CAM capture is neither specific nor consistent.** L1CAM (CD171) expression is not exclusive to neurons; it appears on some glial populations, and L1CAM+ isolation captures only a subset of neuron-derived EVs. The bead-based capture introduces substantial inter-individual variability in yield (Kanemoto et al., 2016, PMID: 27588270).
3. **The "neurodegenerative priming" concept is vague and potentially unfalsifiable.** If a biomarker fails to show early changes, proponents can always argue that "priming" wasn't sufficiently advanced—this framing lacks operational specificity for hypothesis testing.
4. **p-tau231 is elevated in non-AD tauopathies.** Frontotemporal lobar degeneration with MAPT mutations and progressive supranuclear palsy also show elevated p-tau231 in CSF, limiting specificity for AD (Schöll et al., 2017, PMID: